Transformation of Treatment Strategies for ATTR Amyloidosis

The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.